Kala Pharmaceuticals’ KPI-012: Novel Orphan Drug Therapy For PCED
Zorica Nastasic Introduction I give a hold rating to Kala Pharmaceuticals (NASDAQ:KALA). I think the company has an exciting product ...
Friday, November 22, 2024
Tag: KPI012
RECOMMENDED
Get the latest news and follow the coverage of Investing, World News, Stocks, Market Analysis, Business & Financial News, and more from the top trusted sources.